Anthera Pharmaceuticals

Anthera Pharmaceuticals is focused on developing products to treat diseases associated with inflammation and autoimmune diseases.

Launch date

2004

Employees

Market cap

Enterprise valuation

(€7m) (Public information from Sep 2024)

Hayward California (HQ)

Revenues, earnings & profits over time

EUR	2015	2016
R&D budget	28.0m	44.0m

Source: Dealroom estimates

Date	Investors	Amount	Round
Sep 2006	Pappas Capital Sears Capital Management VantagePoint Capital Partners Mitsubishi Sofinnova Ventures	$36.0m	Late VC
Aug 2008	Pappas Capital Caxton Advantage Life Sciences Fund VantagePoint Capital Partners Sofinnova Ventures HBM Healthcare Investments	$19.0m	Late VC
Mar 2010	N/A	N/A	IPO
Sep 2010	OrbiMed Caxton Associates	$31.5m	Post IPO Equity
Jan 2011	Hercules Capital	N/A	Post IPO Debt
Jun 2011*	N/A	$47.0m	Post IPO Equity
Jan 2018	OrbiMed Caxton Associates	$15.0m	Post IPO Equity
Aug 2018	Pappas Capital Caxton Advantage Life Sciences Fund VantagePoint Capital Partners Sofinnova Ventures	$19.0m	Debt
Total Funding		€50.0m

Tech stackLearn more about the technologies and tools that this company uses.

Financials